

1 **A Novel Repertoire of Blood Transcriptome Modules Based on Co-expression Patterns**
2 **Across Sixteen Disease and Physiological States**

3 Matthew C Altman^{1,2,*}, Darawan Rinchai³, Nicole Baldwin⁴, Elizabeth Whalen¹, Mathieu
4 Garand³, Basirudeen Ahamed Kabeer³, Mohammed Toufiq³, Scott Presnell¹, Laurent Chiche⁵,
5 Noemie Jourde-Chiche⁶, J Theodore Phillips⁴, Goran Klintmalm⁴, Anne O'Garra^{7,8}, Matthew
6 Berry⁹, Chloe Bloom⁷, Robert J Wilkinson^{10,11,12}, Christine M Graham⁷, Marc Lipman¹³, Ganjana
7 Lertmemongkolchai¹⁴, Davide Bedognetti³, Farrah Kheradmand¹⁵, Asuncion Mejias¹⁶, Octavio
8 Ramilo¹⁶, Karolina Palucka^{4,17}, Virginia Pascual^{4,18}, Jacques Banchereau^{4,17}, Damien
9 Chaussabel^{1,3*}

10 1 *Systems Immunology, Benaroya Research Institute, Seattle, Washington, USA*

11 2 *Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington,*
12 *USA*

13 3 *Systems Biology, Sidra Medicine, Doha, Qatar*

14 4 *Baylor Institute for Immunology Research and Baylor Research Institute, Dallas, Texas, USA*

15 5 *Department of Internal Medicine, Hospital Europeen, Marseille, France*

16 6 *Aix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France*

17 7 *Laboratory of Immunoregulation and Infection, The Francis Crick Institute, London, UK*

18 8 *National Heart and Lung Institute, Imperial College London, London W2 1PG, UK*

19 9 *Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK*

20 10 *The Francis Crick Institute, London, UK*

21 11 *Department of Medicine, Imperial College, London, UK*

22 12 *Wellcome Center for Infectious Diseases Research in Africa and Department of Medicine,*
23 *Institute of Infectious Diseases and Molecular Medicine, University of Cape Town Observatory*
24 *7925, Republic of South Africa*

25 13 *UCL Respiratory, Division of Medicine, University College London, London, UK*

26 14 *Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of*
27 *Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand*

28 15 *Baylor College of Medicine, Houston, Texas, USA*

29 16 *Nationwide Children's Hospital and the Ohio State University School of Medicine, Division of*
30 *Pediatric Infectious Diseases, Columbus, Ohio, USA*

31 17 *The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA*

32 18 *Weill Cornell Medicine, New York, New York, USA*

33

34 *To whom correspondence may be addressed:

35 Matthew C Altman, MD, Systems Immunology Division, Benaroya Research Institute, 1201

36 Ninth Avenue, Seattle, WA 98101, USA. Tel. +1 206 287 5648, Fax. 206 287 5682, E-mail:

37 maltman@benaroyaresearch.org

38 Damien Chaussabel, PhD, Systems Biology Department, Sidra Medical and Research Center, PO

39 Box 26999 Al Luqta Street, Doha, Qatar. Tel. +974 4003 7395, E-mail: dchaussabel@sidra.org

40

41 **Keywords:** human immunology; transcriptome; gene expression; systems biology; network
42 analysis; modular repertoire

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ABSTRACT

Blood transcriptomics measures the abundance of circulating leukocyte RNA on a genome-wide scale. Dimension reduction is an important analytic step which condenses the number of variables and permits to enhance the robustness of data analyses and functional interpretation. An approach consisting in the construction of modular repertoires based on differential co-expression observed across multiple biological states of a given system has been described before. In this report, a new blood transcriptome modular repertoire is presented based on an expanded range of disease and physiological states (16 in total, encompassing 985 unique transcriptome profiles). The input datasets have been deposited in NCBI public repository, GEO. The composition of the set of 382 modules constituting the repertoire is shared, along with extensive functional annotations and a custom fingerprint visualization scheme. Finally, the similarities and differences between the blood transcriptome profiles of this wide range of biological states are presented and discussed.

66

67

68 **BACKGROUND:**

69 **Blood transcriptomics.**

70 Blood transcriptome profiling approaches have been employed for nearly two decades in
71 a wide range of settings [1-4]. It consists of measuring leukocyte transcript abundance on a
72 genome-wide scale. This application was enabled following the introduction of microarray
73 technologies and more recently of RNA sequencing. Leukocyte transcriptome profiles have more
74 commonly been measured in whole blood or peripheral blood mononuclear cell fractions. But
75 studies have also investigated changes in transcriptome abundance in isolated leukocyte
76 populations as well as in single cells [5, 6]. Global changes in transcript abundance can also be
77 observed upon stimulation of the cells *in vitro* with host or environmental derived immunogenic
78 factors, such as pathogen-associated molecular pattern, antigenic peptides, as well as pro or anti-
79 inflammatory cytokines or chemokines [7, 8].

80 **Dimension reduction approaches.**

81 Approaches that permit organization or reduction of large number of variables being
82 measured are commonly adopted when working with omics datasets. Principal component
83 analysis (PCA) is usually employed as a “first line” dimension reduction strategy. It consists in
84 converting sets of correlated variables into aggregate variables called principal components.
85 Rather than being used to identify gene “signatures” PCA mostly serves to “reveal internal
86 structure of the data in a way that best explains the variance in the data” [9]. For this reason,
87 PCA tends to be performed as one of the first step in the analysis as the information it conveys
88 can direct the design of downstream analyses. For instance, in an experiment where cells from

89 different donors are exposed to stimuli *in vitro* a PCA plot would permit to determine among
90 sample processing batch, donor and stimulation, which of these factors contributes the most to
91 overall variance observed. If stimulations are especially potent they may “override” the variance
92 associated with donor-donor differences. But in cases where stimulations have subtler effects
93 donor-donor differences may be the predominant source of variation.

94 Clustering tends to be used in subsequent analysis steps and is by far the most commonly
95 used dimension reduction approach. It consists in grouping transcripts based on similarities in
96 expression levels. Individual genes can thus be reduced into “signatures”, each constituted by
97 multiple genes that show some degree of correlation. Clustering can be applied either prior to or
98 following feature selection. Clustering methods which are commonly used include hierarchical
99 clustering and k-means clustering.

100 Another less commonly employed approach to dimension reduction relies on the
101 construction and mining of correlation networks. A network is constituted of “nodes” and
102 “edges” (the later are the lines connecting the different nodes to indicate a relationship). Nodes
103 can represent one of many different things e.g.: genes, proteins, samples, individuals etc..;
104 likewise, the nature of the relationship depicted by the edges varies, e.g.: physical interaction,
105 regulation, co-occurrence in literature abstracts. Also the first step when “reading” a network
106 consists in determining what its nodes and edges represent. In a correlation network the nodes
107 represent genes and the edges correlation in level of abundance of their product (RNA in the case
108 of transcriptomic data). The use of correlation networks for transcriptome data analysis has been
109 covered extensively in a recent review by Van Dam et al [10]. One of the approaches most
110 commonly employed for correlation-based expression analysis is Weighted Gene Correlation
111 Network Analysis (WGCNA) [11]. Using a transcriptome dataset as input, it consists in building

112 a weighted correlation network (i.e. edges receive a “connection weight” according to the
113 strength of the correlation). This network is subsequently partitioned into sets of highly
114 correlated genes, referred to as modules, using hierarchical clustering.

115 **Module repertoires.**

116 A first “modular repertoire framework” was developed by our group over 10 years ago,
117 specifically for analysis and interpretation of blood transcriptome data [12] [13]. Such a
118 framework consists of: 1) A collection of transcriptional modules (i.e. the modular repertoire), 2)
119 Functional interpretations for the different modules 3) A fingerprint visualization designed for
120 mapping perturbations of a given modular repertoire (as compared to steady state or appropriate
121 baseline).

122 The construction of a modular repertoire constitutes a dimension reduction step. The
123 approach is similar to network correlation analyses described above: i.e. a network serves as a
124 basis for module selection, its nodes represent genes, and edges connecting the nodes represent
125 gene co-expression. The fact that differential co-expression across distinct biological states for a
126 given system is taken into account may be the most distinctive feature (**Figure 1**). For instance,
127 in the case of blood transcriptomics, the network would factor in whether co-expression between
128 a pair of genes occurs across all the repertoire of pathological or physiological states or only in
129 some of those states. This information is “encoded” in the network used for module construction
130 via the weights which are attributed to each of the edges. Indeed, if ten different states are
131 covered (i.e. ten different input datasets) then the weight of each edge will vary between 1 and
132 10 (co-expression observed in one state/dataset or up to 10 states/datasets). As will be further
133 described in the article each module can subsequently be linked to the specific states in which its
134 constitutive genes were co-expressed.

135 To date two “modular repertoires frameworks” have been constructed and used for
136 analysis and interpretation of whole blood transcriptome profiling data. A first repertoire based
137 on 8 disease states was published in 2008 (**Table 1**) [12]. The total combined number of samples
138 across the 8 input datasets was 239. Transcriptome profiles were generated from purified
139 peripheral blood mononuclear cells using Affymetrix GeneChips. Five years later a second
140 repertoire based on 7 disease states and a total of 410 samples was constructed [14].
141 Transcriptome profiles were in this case generated from whole blood using Illumina Beadarrays.
142 Input datasets encompass a wide breadth of biological states on which basis the weighted co-
143 expression network was built. This included patients with autoimmune diseases (systemic lupus),
144 inflammatory conditions (systemic onset juvenile arthritis), viral and bacterial infections (e.g.
145 *Staphylococcus* infection, HIV, Influenza, RSV) or cancer (stage IV melanoma). Since
146 perturbations across a wide range of states is factored into the construction of the repertoire it
147 should prove suitable as a generic framework for interpretation of blood transcriptome datasets.
148 This appears to indeed be the case given the extent to which the two repertoire framework which
149 have been previously published have been reused (**Figure 2**).

150 Attempts were made at assigning functional interpretations to the modules constituting
151 the framework. A common misconception is that function is used as a basis for the construction
152 of modular repertoires. In fact, module construction is entirely data-driven and putative functions
153 are only assigned afterwards based on gene ontology or pathway enrichment analysis the gene
154 sets constituting each of the modules are subjected to.

155 Visualization is another important element when it comes to interpretation of high
156 dimensional data. Reducing the dimension of datasets from tens of thousands of variables to a
157 few hundred opens new possibilities with that regard. A fingerprint representation was

158 introduced along with the first generation of module repertoires published in 2008. It consists in
159 fixing the position of individual modules on a grid. At each position a spot would indicate
160 compared to a baseline either increase in abundance for transcripts constituting the module (in
161 red) or decrease in abundance (in blue). Functional interpretations can also be mapped to the grid
162 to aid interpretation of the results.

163 This article serves on one hand as a resource, making available a new blood modular
164 transcriptome repertoire, along with: 1) the algorithm used for its construction, 2) the 16 input
165 datasets, each representing a different disease or physiological state; 3) functional interpretations,
166 along with underlying functional/literature profiles; and 4) a new fingerprint representation. It
167 provides on the other hand a high-level unbiased molecular classification of a wide range of
168 immunological processes involved in health maintenance and pathogenesis.

169

170 **METHODS:**

171 **Study subjects**

172 Module construction: Gene expression datasets from 985 de-identified subjects from
173 distinct cohorts from the Baylor Institute for Immunology Research (BIIR) were used for this
174 study. Each of those studies was approved by the Baylor Institutional Review Board (IRB #'s
175 009-240, 006-177, 002-197, 009-257, H-18029, HE-470506). Gene expression datasets were
176 selected to cover major classes of immune states (**Table 2**), were required to have a minimum of
177 25 total samples, and at least 20% of the total samples were required to be appropriately matched
178 controls.

179 **RNA extraction and processing**

180 Whole blood for all sample sets were collected into Tempus Blood RNA Tubes (Thermo
181 Fisher Scientific). Total RNA was isolated from whole blood lysate using MagMAX for
182 Stabilized Blood Tubes RNA isolation kit for Tempus Blood RNA Tubes (Thermo Fisher
183 Scientific). RNA quality and quantity were assessed using Agilent 2100 Bioanalyzer (Agilent
184 Technologies) and NanoDrop 1000 (NanoDrop Products, Thermo Fisher Scientific). Samples
185 with RNA integrity numbers values >6 were retained for further processing.

186 **Microarray analysis**

187 Gene expression profiles from whole blood samples generated using Illumina HumanHT-
188 12 v3.0 or Illumina HumanHT-12 v4.0 expression BeadChips were obtained for 16 groups of
189 patients selected as above. Sixteen datasets were used as input (Table 1). Each dataset's
190 expression data was preprocessed and clustered independently of the rest. First probes were
191 discarded if they were not present (detection $P < 0.01$) in at least ten samples or in at least ten
192 percent of the samples, whichever was greater. Then, the sample data for each dataset was
193 normalized using the BeadStudio average normalization algorithm. Once normalized, the signal
194 was floored such that all signals less than ten were set to ten. Then, the fold change was
195 calculated relative to the median signal for that probe across all samples. If the difference
196 between a signal and the probe's median signal was less than 30, or the calculated absolute
197 magnitude of the fold change was less than 1.2, the fold change was set to 1 in order to reduce
198 noise from low-level responses. At this stage, probes were filtered again. Probes were retained
199 only if they had a calculated absolute fold change greater than 1 in at least ten samples or in at
200 least ten percent of the samples, whichever was greater. Finally, the data was transformed to the
201 \log_2 of the calculated fold changes.

202 **Module construction algorithm**

203 Sets of coordinately regulated genes, or transcriptional modules, were extracted from the
204 whole blood microarray datasets. Each of the preprocessed microarray datasets was clustered in
205 parallel using Euclidean distance and the Hartigan's K-Means clustering algorithm. The 'ideal'
206 number of clusters (k) for each dataset was determined within a range of k=1 to 100 by means of
207 the jump statistic [15] . Taking the sixteen sets of clusters as input (**Table 2**), we constructed a
208 weighted co-cluster graph [12, 16] . To select modules, we employed an iterative algorithm to
209 extract sets of probes that are most frequently clustered together in the same datasets, proceeding
210 from the most stringent requirements to the least as previously described [12] . This iteration
211 differed from previous implementation of this algorithm in that the k was calculated
212 independently for each dataset cluster and the size of the core sub-networks was smaller (10
213 probes). The algorithm also was changed from previous implementations to ensure that the core
214 sub-networks co-clustered in the same datasets. Further details and an example of the code are
215 included in the supplemental methods (**Supplementary File 1**). The resulting 382 module set
216 constitutes the third generation of modular blood transcriptome repertoire constructed since the
217 initial publication in 2008 [12] of the first generation, and in 2013 of the second [14].

218 **Module annotation**

219 Module gene lists were investigated using Database for Annotation Visualization and
220 Integrated Discovery (DAVID) version 6.7[17, 18] . This database uses a modified Fisher exact
221 test to identify specific biological/functional categories that are overrepresented in gene sets in
222 comparison with a reference set (the human genome was used as the reference set). The top
223 matched DAVID annotation cluster (using default settings), the top matched canonical pathway
224 from Kyoto encyclopedia of genes and genomes (KEGG), the top matched pathway from

225 BioCarta, and the top matched Gene Ontology biologic process (GO_BP) and molecular function
226 (GO_MF) terms were identified for each module. Each module was also investigated for
227 significant overlap with 2 other established blood transcriptome module repertoires[14, 19] .
228 These findings are summarized in the module annotation spreadsheet (**Supplemental File 2**).

229 Literature profiling: Acumenta Biotech Literature Lab™ (LitLab) was used to associate
230 genes within a particular module to terms in PubMed abstracts [20]. Association scores reflecting
231 the strength of the associations were used to calculate the “Product Scores”. The top 3 terms that
232 showed the strongest association and highest “Product Scores” were used to create the functional
233 annotation. A similar approach using LitLab has been previously reported [7]. The steps taken to
234 annotate all 382 modules is described briefly here. All statistical analyses were performed using
235 Microsoft Excel (2010) with Visual Basic for Applications (VBA), Linux-based command line
236 in Mac OS, and R statistical software.

237 The first part into the construction of a Product Scores table consist of listing all the term
238 available in LitLab (over 80,000). Next genes in each module were submitted as a list to LitLab
239 Editor and manually validated using LitLab’s built-in validation tool and/or NCBI Gene
240 (<https://www.ncbi.nlm.nih.gov/gene>) prior to submission for analysis using all domains
241 available. After the analysis was completed the summary result page was exported to an xls file.
242 Using UNIX command line, the exported files were converted to csv files with the filename
243 appended in the last column of each row and vertically appended. The “merged” file was used to
244 populate the table including all available LitLab terms. The top 3 terms with highest Product
245 Scores were selected to represent the module functional annotation and are tabulated in column I
246 of the module annotation table (**Supplementary file 2**).

247

248 **Module grid visualization**

249 Modules were arranged on a grid based on similarities in patterns of activity across the 16 input
250 datasets, each of them corresponding to a different pathological or physiological state. First,
251 modules were partitioned using K-means clustering, which resulted in the constitution of 38
252 clusters. Given the possibility of collapsing values of the modules constituting each cluster in a
253 single “aggregate” value the term “module aggregate” was used to designate each cluster (A1 to
254 A38). Of these 38 k-means clusters, 27 comprised of more than one module. Modules were next
255 arranged on a grid with each row corresponding to modules belonging to the same aggregate
256 (Figure 4). Therefore, the total number of row on the grid equals 27 and number of columns
257 equals the largest number of modules for a given aggregate, which is 42 (for aggregate A2). For
258 each module the highest of the two values indicating increase or decrease is selected for
259 visualization (e.g. if % increase > % decrease, then a red sport representing % increase is
260 shown).

261

262

263 **RESULTS:**

264 **Input datasets**

265 Sixteen datasets were used as input for the construction of a third blood transcriptome
266 module repertoire. This collection encompasses 985 individual whole blood transcriptome
267 profiles. All the samples were processed in the same facility and and run on Illumina HT12
268 beadarrays. Each dataset corresponds to a different pathological or physiological state. The range
269 has been expended considerably compared to the first and second repertoires which were
270 published previously (**Table 1**).

271 Some “core” pathologies are again covered, with for instance systemic lupus
272 erythematosus, systemic onset juvenile idiopathic arthritis, liver transplant recipients under
273 immunosuppression and patients with metastatic melanoma, which are represented in all three
274 versions. Infectious diseases are again well represented, including viral respiratory viruses,
275 influenza and RSV, as well as HIV and infections caused by *Mycobacterium tuberculosis*,
276 *Staphylococcus aureus*, or *Burkholderia pseudomallei* (agent of Melioidosis).

277 New to this third framework are inflammatory conditions of the skin, lung or circulation
278 (COPD, juvenile dermatomyositis, Kawasaki disease, respectively. A neurogenerative disease
279 (MS). Primary immune deficiency (B-cell deficiency) and physiological variant, pregnancy.

280 Absent from this repertoire, which were represented earlier are type 1 diabetes and
281 *Escherichia coli* infection. The intent while constituting the collection of input dataset was to
282 capture a wide breadth of immunological response or perturbations (e.g. interferon responses,
283 inflammation, autoimmune processes, tolerance, "loss" of a leukocyte population) as to be able
284 to construct a "generic" modular repertoire. Number of samples included in each of the datasets
285 are provided in the methods section and in **Table 2**. The datasets have been deposited in the
286 NCBI Gene Expression Omnibus, GEO (GSE100150).

287

288 **Module repertoire construction**

289 The algorithm employed for construction of the module repertoire is described in details
290 in the supplementary methods section. Pseudocode is also provided to facilitate implementation
291 in different programming language. The major steps are also described in **Figure 3**. Briefly: 1)
292 input datasets are assembled; 2) transcripts which show no or very little expression across all
293 conditions are filtered out; 3) clustering is performed for each individual dataset; 4) a weighted
294 co-expression network is constructed, where edges between the genes represent at least one co-
295 clustering event in one of the input datasets. Weight is assigned based on the total number of co-
296 clustering events (up to 16, when co-clustering between the pair of genes occurs in all input
297 datasets); 5) The resulting network is mined to identify highly inter-connected sub-networks,
298 which form modules. The approach takes into account weights since the first sub-networks to be
299 "extracted" are those with the highest number of states in which co-clustering is observed.

300 This approach captures relationships that exist among constitutive elements of our
301 biological system (blood) and the given range of disease states. It is unbiased in that it does not
302 rely on any previous information about interactions among genes or knowledge about the gene

303 function. Using this technique, from >47,000 total transcripts, 15132 total transcripts passed the
304 expression filter and 382 modules were identified which consist of 14,502 of those transcripts
305 (95.8%).

306

307 **Blood transcriptome modular repertoire**

308 The output of the module repertoire construction process is a collection of gene sets, aka
309 “modules”. The gene composition of each of the 382 module which were identified is provided
310 in a supplemental file (Column D: Number of unique genes; Column E: Illumina probe IDs; and
311 column F: symbols of member genes). Average number of unique constitutive genes per module
312 is 37.1, median is 26.5 and range is 12 – 169. Extensive functional profiling was also carried out
313 with, enrichment results provided for: a) Literature lab abstract keyword profiling (column I)
314 [ref], b) DAVID (columns J-L) [ref], KEGG (columns N-P), Biocarta (columns R-T) [ref],
315 OMIM (columns U-X), GOTERM (columns Y-AF). In addition, extent of overlap with the
316 previous modular repertoire as well as with a set of modules constituted at Emory university [19]
317 is presented in columns AG-AN.

318 Taken together outputs from this wide range of functional enrichment analyses was
319 employed to assign, when possible, a consensus functional association title for modules (column
320 C). For instance, M16.3 (145 genes) shows the following enrichment pattern (encompassing,
321 literature terms, pathways, diseases, ontologies in columns I through AF): T-Lymphocytes,
322 Lymphocytes / Structure_of_Caps_and_SMACs; Ikaros_and_signaling_inhibitors / Primary
323 immunodeficiency / Lck and Fyn tyrosine kinases in initiation of TCR Activation / lymphocyte
324 activation / phosphatase activity. While some of the terms may appear rather cryptic or lack
325 specificity based on overall convergence “T-cell” was the consensus functional annotation title

326 assigned for this module. However, for the majority of modules functional annotations did not
327 show sufficient convergence, or were too few for a consensus annotation to be assigned and
328 received instead the TBD label (279 out of 382 modules).

329 **Module-level analyses**

330 For each module the proportion of its constitutive transcripts which abundance levels
331 differ between study groups is determined (e.g. cases vs controls; pre-treatment vs post-
332 treatment). Two values are computed, corresponding to percent of transcripts increased and
333 percent of transcripts decreased. Cutoffs employed to determine change can be adjusted based on
334 study design and level of tolerance for false positives or negatives chosen by the user. For
335 instance, for group comparisons cutoffs can be based both on statistics, fold changes and/or
336 differences with or without multiple testing correction (e.g. p-value <0.01, FC = 1.5, Diff = 50,
337 FDR = 0.1).

338 Comparisons can also be made at the individual subject level (e.g. one case vs controls).
339 When comparing an individual sample to a control group a combined fold change and difference
340 cutoff can be used (e.g. FC = 1.5, Diff = 50). Alternatively, the cutoff can be adjusted based on
341 variance observed for each individual module among the control group samples (cutoff = means
342 of control \pm 2SD).

343 **Fingerprint grid plot visualization**

344 Differential expression at the module level can be displayed as a “fingerprint”, where the
345 percentage of differentially expressed genes for a given module is represented by either a red
346 spot or a blue spot, indicating increased abundance and decreased abundance for the constitutive
347 transcripts, respectively (**Figure 4**). Each module is assigned a fixed position on a grid plot
348 (coordinate on the grid; i.e. rows and columns). The number and intensity of the spots may

349 denote quantitative differences, sometimes correlated for instance with disease severity.
350 Differences in distribution of the spots on the grid and their color may denote qualitative
351 differences.

352 Such fingerprint grid plots were generated along with each of the two previous versions
353 of blood transcriptome module repertoires. In those earlier versions the modules were arranged
354 based on the order in which they were identified when running the script for module
355 construction, which is based on weight and module size. However, for the third version
356 presented here modules are arranged on the grid instead based on similarities in transcriptional
357 patterns across the 16 input datasets. This is described in more details in the materials and
358 methods section. A consequence of adopting this approach is that each row on the grid is
359 constituted by modules for which changes in expression levels is often coordinated (**Figure 4**,
360 module grid on the right). It means that, when mapping changes for a given disease, modules on
361 the same row tend to follow the same trend (increase or decrease), which makes the fingerprint
362 easier to read. It also means that a certain degree of functional convergence can be found for a
363 given row of modules. This is for instance the case of row A28, which comprises 6 distinct
364 “interferon modules”.

365 In the example provided in Figure 4 transcriptome profiles of 55 pediatric patients with
366 SLE and 14 control subjects are compared. As was previously reported an interferon signature
367 dominated the response (A28), and was accompanied by modules associated with cell cycle (A27
368 and A29, including antibody production). Increase in abundance levels of modules associated
369 with inflammation and neutrophils, another hallmark of the lupus transcriptome signature, was
370 also observed (A35). These changes were also accompanied by decrease in transcript abundance,
371 which was more apparent for some modules that belong to A1, A2 and A3. More specifically,

372 under A1, the most marked decreases were observed for modules which the functional map
373 associates with protein synthesis (dark purple color, at positions 1, 5, 11 and 19 on row A1).

374 One may even go one step further and “aggregate” changes observed by row, further
375 reducing dimension for a given dataset from 382 modules to 27 “aggregates” (**Figure 4**, module
376 aggregates on the left). While employing the simplest framework possible would generally be
377 best, our earlier work shows that distinct interferon modules are biologically and clinically
378 meaningful [21]. Whether to work at the module-level or aggregate-level would depend then on
379 the desired level of resolution.

380 Module grid plots are provided for each disease / physiological state in a supplementary
381 file (**Supplementary file 3**). Six such module fingerprints representative of the range of
382 signatures observed are shown in **Figure 5**. Blood transcriptome perturbations were for instance
383 most widespread in the case of both MS and *S. aureus* infection (top panels) but with opposite
384 patterns of changes, which will be even more apparent when profiles are compared directly
385 across all 16 states (**Figure 6**). Changes associated with COPD or stage IV melanoma (middle
386 panels) were most subtle but nonetheless distinct, with differences in abundance vs controls
387 subjects most visible for aggregates A24 through A26 (Oxydative phosphorylation, Monocytes,
388 Inflammation), and A36 through A38 (“erythrocytes”, “neutrophil activation”). In the case of
389 SLE and TB (bottom panels) interferon signatures constituted a common trait (A28) but with at
390 the same time opposite patterns observed for an aggregate which was directly adjacent (A29: cell
391 cycles). Other subtler differences in intensity of sets of modules associated with inflammation
392 were also observed between these two diseases (A33-A35).

393 **Heatmap visualization**

394 A more traditional heatmap visualization can also be employed to represent module-level
395 or module aggregate-level data. One configuration has module aggregates set as rows and

396 disease/physiological states as columns (**Figure 5**). Hierarchical clustering can then be used to
397 arrange states on the heatmap based on similarities in abundance profiles across module
398 aggregates. Such a heatmap permits to explore high-level similarities in blood transcriptome
399 profiles across all 16 states. The first order of separation groups in one cluster a rather
400 unexpected set of diseases, which are: acute HIV infection, Multiple sclerosis, Juvenile
401 Dermatomyositis and COPD. All remaining 14 states are grouped in a second cluster, with RSV
402 figuring as an outlier. The main trend driving the dichotomy between the first four diseases and
403 the rest was an overall suppression of modules associated with inflammation / myeloid cell
404 responses (A34-A38), accompanied by an increase in modules corresponding to aggregates A1
405 through A8 which are in part associated with lymphocytic responses. The factors underlying
406 these two distinct “overarching” signatures are unclear. Diseases belonging to either group can
407 display marked interferon signatures (e.g. acute HIV infection on one hand and SLE or Influenza
408 infection on the other). The dichotomy does not appear to run along the traditional Th1/Th2
409 paradigm either, nor does it seem to reflect organ involvement.

410 Another heatmap configuration consists in arranging disease/physiological states as rows
411 and modules belonging to a given aggregate as columns (**Figure 7**). In the example shown on
412 figure 6, modules constituting the A28 aggregate were used. These modules are annotated
413 functionally as “interferon modules”. In this case, as could be expected, the dichotomy obtained
414 separates diseases or states in which interferon signatures are present (all infectious diseases,
415 with the notable exception of *S aureus* sepsis, systemic autoimmune/autoinflammatory
416 diseases such as SLE, SoJIA and liver transplant recipients under immunosuppressive therapy),
417 from those in which interferon signatures are absent (JDM, Kawasaki disease, B-cell deficiency)
418 and even possibly repressed (COPD, Melanoma, Pregnancy and MS).

419

420 **DISCUSSION:**

421 Improvements compared to the two earlier version of published blood module repertoires
422 include: 1) the expansion of the number and range of biological states included for module
423 construction to 16, encompassing nearly 1000 individual transcriptome profiles; 2) the grouping
424 modules on the fingerprint grid based on similarities in activity profiles across diseases. This
425 later development allows on one hand accommodating for the larger number of modules
426 identified in this version (384) and on the other adds another level of dimension reduction with
427 the possibility to analyze and visualize blood transcriptome changes at the “module aggregate
428 level” (27 aggregates).

429 Further improvements may of course already be envisioned for subsequent versions of
430 blood modular repertoire, with for instance the use of blood transcriptome datasets generated via
431 RNAsequencing as input, or the possible introduction of more robust clustering methods as a
432 basis for the construction of weighted co-clustering networks. Another direction to explore next
433 could also include development of more specialized repertoires, focusing for instance on a given
434 spectrum of diseases (e.g. neurogenerative disorders, respiratory illnesses).

435 Compared to earlier versions of modular repertoires reusability should be facilitated by
436 the availability of R Scripts which have been developed to perform module repertoire analyses
437 and generate grid or heatmap fingerprint visualizations. These scripts will be available on
438 GitHub and described in detail in a separate publication (in preparation, early draft to be
439 deposited shortly in BioRxiv). These bioinformatics tools were recently used as a basis for a
440 weeklong workshop organized at the Sorbonne Universite’s Inflammation-Immunopathology-
441 Biotherapy Department. Hands-on training activities included the analyses by participants of

442 several public blood transcriptome datasets generated using samples obtained from patients with
443 RSV infection and control subjects. This exercise also permitted to compare aggregate-level
444 modular RSV fingerprint obtained across the six different studies. Furthermore, the
445 heterogeneity at the level of individual patients observed with and across RSV dataset was
446 explored, leading to the characterization of several modular RSV signatures “endotypes”.

447 Finally, this third generation of blood modular repertoires also served as a backbone for
448 development of cost-effective assays that can be substituted for genome-wide screens in
449 biomarker discovery and in immune phenotyping or monitoring (Altman et al. manuscript in
450 preparation and to be submitted to BioRxiv). The so-called transcriptome fingerprint assays are
451 based on down-selecting to the most representative genes (i.e. surrogate genes) within each
452 module. This can be achieved via a purely unsupervised data driven methodology. Such assays
453 will be able to recognize changes occurring at the global level (as the original modular
454 repertoire), while ensuring practicality, and cost effectiveness in that it can be performed using
455 sensitive 'meso-scale' profiling assay (interrogating tens or hundreds of transcripts) such as high-
456 throughput PCR, or targeted RNA sequencing.

457

458

459 REFERENCES

- 460 1. Banchereau, R., et al., *Understanding Human Autoimmunity and Autoinflammation*
461 *Through Transcriptomics*. *Annu Rev Immunol*, 2017. **35**: p. 337-370.
- 462 2. Chaussabel, D., *Assessment of immune status using blood transcriptomics and potential*
463 *implications for global health*. *Semin Immunol*, 2015. **27**(1): p. 58-66.
- 464 3. Devaux, Y., *Transcriptome of blood cells as a reservoir of cardiovascular biomarkers*.
465 *Biochim Biophys Acta Mol Cell Res*, 2017. **1864**(1): p. 209-216.
- 466 4. Sumitomo, S., et al., *Transcriptome analysis of peripheral blood from patients with*
467 *rheumatoid arthritis: a systematic review*. *Inflamm Regen*, 2018. **38**: p. 21.

- 468 5. Crinier, A., et al., *High-Dimensional Single-Cell Analysis Identifies Organ-Specific*
469 *Signatures and Conserved NK Cell Subsets in Humans and Mice*. *Immunity*, 2018. **49**(5):
470 p. 971-986 e5.
- 471 6. Villani, A.C., et al., *Single-cell RNA-seq reveals new types of human blood dendritic*
472 *cells, monocytes, and progenitors*. *Science*, 2017. **356**(6335).
- 473 7. Alsina, L., et al., *A narrow repertoire of transcriptional modules responsive to pyogenic*
474 *bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4*.
475 *Nat Immunol*, 2014. **15**(12): p. 1134-42.
- 476 8. Cepika, A.M., et al., *A multidimensional blood stimulation assay reveals immune*
477 *alterations underlying systemic juvenile idiopathic arthritis*. *J Exp Med*, 2017. **214**(11):
478 p. 3449-3466.
- 479 9. Narayan, R., *Encyclopedia of Biomedical Engineering*. 2018: Elsevier.
- 480 10. van Dam, S., et al., *Gene co-expression analysis for functional classification and gene-*
481 *disease predictions*. *Brief Bioinform*, 2018. **19**(4): p. 575-592.
- 482 11. Zhang, B. and S. Horvath, *A general framework for weighted gene co-expression network*
483 *analysis*. *Stat Appl Genet Mol Biol*, 2005. **4**: p. Article17.
- 484 12. Chaussabel, D., et al., *A modular analysis framework for blood genomics studies:*
485 *application to systemic lupus erythematosus*. *Immunity*, 2008. **29**(1): p. 150-64.
- 486 13. Chaussabel, D. and N. Baldwin, *Democratizing systems immunology with modular*
487 *transcriptional repertoire analyses*. *Nat Rev Immunol*, 2014. **14**(4): p. 271-80.
- 488 14. Obermoser, G., et al., *Systems scale interactive exploration reveals quantitative and*
489 *qualitative differences in response to influenza and pneumococcal vaccines*. *Immunity*,
490 2013. **38**(4): p. 831-44.
- 491 15. Sugar, C.A. and G.M. James, *Finding the Number of Clusters in a Dataset*. *Journal of the*
492 *American Statistical Association*, 2003. **98**(463): p. 750-763.
- 493 16. Chaussabel, D. and N. Baldwin, *Democratizing systems immunology with modular*
494 *transcriptional repertoire analyses*. *Nat Rev Immunol*, 2014. **14**(4): p. 271-280.
- 495 17. Huang, D.W., B.T. Sherman, and R.A. Lempicki, *Bioinformatics enrichment tools: paths*
496 *toward the comprehensive functional analysis of large gene lists*. *Nucleic Acids*
497 *Research*, 2008. **37**(1): p. 1-13.
- 498 18. Huang, D.W., B.T. Sherman, and R.A. Lempicki, *Systematic and integrative analysis of*
499 *large gene lists using DAVID bioinformatics resources*. *Nat Protoc*, 2008. **4**(1): p. 44-57.
- 500 19. Li, S., et al., *Molecular signatures of antibody responses derived from a systems biology*
501 *study of five human vaccines*. *Nat Immunol*, 2014. **15**(2): p. 195-204.
- 502 20. Febbo, P.G., et al., *Literature Lab: a method of automated literature interrogation to*
503 *infer biology from microarray analysis*. *BMC Genomics*, 2007. **8**: p. 461.
- 504 21. Chiche, L., et al., *Modular transcriptional repertoire analyses of adults with systemic*
505 *lupus erythematosus reveal distinct type I and type II interferon signatures*. *Arthritis*
506 *Rheumatol*, 2014. **66**(6): p. 1583-95.

507 **ABBREVIATIONS**

508 BIIR: Baylor Institute for Immunology Research

509 COPD: Chronic Obstructive Pulmonary Disease

510 DAVID: Database for Annotation Visualization and Integrated Discovery

511 FC: Fold Change

512 FDR: False Discovery Rate

513 GO_BP: Gene Ontology Biologic Process

514 GO_MF: Gene Ontology Molecular Function

515 HIV: Human Immunodeficiency Virus

516 IFN: Interferon

517 IRB: Institutional Review Board

518 KEGG: Kyoto Encyclopedia of Genes and Genomes

519 MS: Multiple Sclerosis

520 PCR: Polymerase Chain Reaction

521 PID: Primary Immune Deficiency

522 ROC: Receiver Operating Characteristic

523 RSV: Respiratory Syncytial Virus

524 SLE: Systemic Lupus Erythematosus

525 SOJIA: Systemic onset Juvenile Idiopathic Arthritis

526 TB: Tuberculosis

527 TBD: To Be Determined

528 **DECLARATIONS**

529 Ethics approval and consent to participate

530 Each of the studies contributing samples for this manuscript was independently approved by the
531 BIIR IRB (IRB #'s 009-240, 006-177, 002-197, 009-257, H-18029, HE-470506, 011-173).

532 **AVAILABILITY OF DATA AND MATERIAL**

533 Raw gene expression data was deposited in the Gene Expression Omnibus,
534 <https://www.ncbi.nlm.nih.gov/geo/>, under the accession GSE100150.

535 **COMPETING INTERESTS**

536 The authors declare no conflicts of interest.

537 **FUNDING**

538 This project has been funded in part with Federal funds from the National Institutes of Health
539 under contract number U01AI082110. Authors affiliated with Sidra Medicine, a member of the
540 Qatar foundation for Education, Science and Community development are supported entirely by
541 institutional funding. RJW is supported by wellcome (203135, 104803), NIH (U01AI115940)
542 and Francis Crick Institute which receives funding from wellcome (FC10218), CR UK
543 (FC10218) and UKRI (FC10218).

544 **AUTHOR'S CONTRIBUTIONS**

545 Conceptualization: MA, DR, NB, DC. Data curation: NB. Visualization: MA, DR, DC. Analysis
546 and interpretation: MA, DR, NB, EW, MG, BK, MT, DC. Resources: CQ, SP, PK, VG, LC, NJ,
547 PL, TP, GK, ML, HR, AG, MB, CB, ML, RW, CG, GL, MC, JS, FK, AM, OR, KP, VP,
548 JB. Writing of the first draft: DC. Funding acquisition: GK, KP, VP, OR, JB, DC. Methodology
549 development: MA, DR, NB, EW. Writing – review & editing: MA, DR, NB, EW, MG, BK, MT,
550 CQ, SP, PK, VG, LC, NJ, PL, TP, GK, ML, HR, AG, MB, CB, ML, RW, CG, GL, MC, JS, FK,
551 AM, OR, KP, VP, JB, DC. The contributor's roles listed above follow the Contributor Roles

552 Taxonomy (CRediT) managed by The Consortia Advancing Standards in Research

553 Administration Information (CASRAI) (<https://casrai.org/credit/>).

554 **ACKNOWLEDGEMENTS**

555 We thank Quynh-Anh Nguyen, Kimberly O'Brien, Dimitry Popov, Michael Mason, and Cate

556 Speake for technical assistance.

557 **FIGURE LEGENDS**

558 **Figure 1: Construction of weighted co-clustering networks.** Weighted co-clustering networks
559 are used as a basis for the construction of modular repertoires. A distinctive characteristic of such
560 networks is that they factor in differences in co-expression across different “states” of the
561 biological system. For the blood transcriptome these states would be different diseases or
562 physiological phenotypes. The weighting of the network is illustrated on this figure. Under
563 scenario A the genes are co-expressed in all three disease states. The weight attributed to the
564 edges of the network on the right is three. Under scenario B and C, co-clustering only occurs in
565 two or one of the disease states, resulting in attributions of weights of 2 and 1, respectively.

566 **Figure 2: Reuse of successive generations of blood modular repertoires.** Two successive sets
567 of blood modular repertoires were published previously, the first one in 2008 and the second in
568 2013. Citations were surveyed to ascertain the extent to which such “frameworks” can be
569 subsequently reused. On these circular plot distinctions are made between self and third party
570 reuse. Results are further broken down by disease areas.

571 **Figure 3: Overview of the module repertoire construction process.** Briefly, the starting point
572 for the construction of blood transcriptional module repertoire is a collection of transcriptome
573 datasets. In this case 16 datasets spanning a wide range of immunological and physiological
574 states were employed. First of all each dataset is independently clustered via k-means clustering.
575 Next, gene co-clustering events are recorded in a table, where the entries indicate the number of
576 datasets in which co-clustering was observed for a given gene pair. Subsequently the co-
577 clustering table serves as input for the generation of a weighted co-clustering graph (as illustrated
578 in Figure 1), where nodes represent genes and edges represent co-clustering events. The largest,
579 most highly weighted subnetworks among a large network constituted of 15,132 nodes are
580 identified mathematically and assigned a module ID. The genes constituting this module are
581 removed from the selection pool and the process is repeated resulting in the selection of 382
582 modules constituted by 14,502 transcripts.

583 **Figure 4: Fingerprint grid plot.** Modules are attributed a fixed position on a grid. Increase in
584 abundance of the transcripts constitutive of a given module is represented by a red spot. Decrease
585 in abundance is represented by a blue spot. Modules arranged on a given row belong to a module
586 aggregate (noted A1 to A38). Changes at the “aggregate-level” are represented by spots to the
587 left of the grid next to the denomination for the corresponding aggregate. In addition a module
588 annotation grid is provided below where a color key indicates functional associations attributed
589 to some of the modules on the grid.

590 **Figure 5: Fingerprint grid plots mapping transcriptome repertoire perturbations across six**
591 **representative disease states.** Each grid represents changes in abundance observed at the
592 module-level in subject from different disease groups compared to their respective controls.
593 Modules occupy a fixed position on the grid, with red spots indicating the proportion of
594 transcripts constitutive of a given module for which abundance is significantly increased and
595 blue spots indicating conversely the proportion of constitutive transcripts for which abundance is
596 decreased.

597 **Figure 6: Patterns of abundance of module aggregates across 16 disease or physiological**
598 **states.** Each column on this heat map corresponds to a “module aggregate”, numbered A1 to
599 A38 (minus A9-A14 and A19-A24 which each included only one module). Each row on the
600 heatmap corresponds to one of the 16 datasets used for construction of the module framework. A
601 red spot on the heatmap indicates an increase in abundance of transcripts comprising a given
602 module cluster for a given disease or physiologic state. A blue spot indicates a decrease in
603 abundance of transcripts. No color indicates no changes. Disease or physiological states were
604 arranged based on similarity in patterns of aggregate activity via hierarchical clustering.

605 **Figure 7: Patterns of abundance of the six interferon modules constituting aggregate A28**
606 **across 16 disease or physiological states.** Each column on this heat map corresponds to one of
607 6 interferon modules constituting the module aggregate A28. Each row corresponds to one of the
608 16 datasets used for construction of the module framework. A red spot on the heatmap indicates
609 an increase in abundance of transcripts comprising a given module cluster for a given disease or
610 physiologic state. A blue spot indicates a decrease in abundance of transcripts. No color indicates
611 no changes. Disease or physiological states and modules were arranged via hierarchical
612 clustering` based on similarity in patterns of aggregate activity.

613 **TABLES**

614 **Table 1: Comparison of the characteristics of the input datasets used for the construction of three**
 615 **consecutive generations of blood transcriptome module repertoires.**

	Generation 1	Generation 2	Generation 3
Number of States	8	7	16
States			
Systemic onset juvenile idiopathic arthritis	X	X	X
Pediatric systemic lupus erythematosus	X	X	X
Juvenile dermatomyositis			X
Type 1 Diabetes	X		
Multiple sclerosis			X
Kawasaki disease			X
COPD			X
Tuberculosis		X	X
<i>Burkholderia pseudomallei</i> infection		X	X
Respiratory Syncytial Virus infection			X
Influenza virus infection	X		X
Human Immunodeficiency Virus infection		X	X
<i>Escherichia coli</i> infection	X		
<i>Staphylococcus aureus</i> infection	X		X
B-cell deficiency			X
Liver transplant recipients	X	X	X
Metastatic melanoma	X	X	X
Pregnancy			X
Number of Input Datasets	8	9	16
Number of individual Profiles	239	410	985
Sample source	PBMCs	Whole Blood	Whole Blood
Platform	Affymetrix U133A&B	Illumina Hu6 v2	Illumina HT12 v3.0
Rounds of module selection	3	8	15
Number of modules	28	260	382
Year published & reference	2008 [ref]	2013 [ref]	Current work

616

617 **Table 2: Datasets used for module construction**

618 Sixteen distinct datasets were used as input for module repertoire construction. Each dataset
 619 corresponds to a different condition or physiological state and comprises both cases and matched
 620 controls. Each dataset was processed as a single batch at the same facility with the data generated
 621 using Illumina HumanHT-12 v3.0 Gene Expression BeadChips. In total the collection comprises
 622 a total of 985 individual transcriptome profiles.

623

624

Dataset	Category	# Samples (Cases)	# Samples (Control)	# Samples (Total)
---------	----------	-------------------	---------------------	-------------------

1 Staphylococcus aureus	Bacterial Infection	99	44	143
2 Burkholderia pseudomallei	Bacterial Infection	35	12	47
3 Tuberculosis	Bacterial Infection	23	11	34
4 Influenza	Viral Infection	25	14	39
5 RSV	Viral Infection	70	14	84
6 HIV	Viral Infection	28	35	63
7 Pediatric SLE	Autoimmune	55	14	69
8 Multiple Sclerosis	Autoimmune	34	22	56
9 Juvenile Dermatomyositis	Autoimmune	40	9	49
10 Kawasaki disease	Autoinflammatory	21	23	44
11 Systemic Onset Idiopathic Arthritis	Autoinflammatory	62	23	85
12 COPD	Inflammatory	19	24	43
13 Melanoma	Malignancy	22	5	27
14 Pregnancy	Physiologic variant	25	20	45
15 Liver transplant recipients	Immunosuppressed	94	30	124
16 B-cell deficiency	Immunodeficiency	20	13	33

625

626 **Supplementary File 1: Module generation and pseudocode**

627 This word document describes the algorithm employed for the construction of this modular
628 repertoire framework along with pseudocode which may be used as a basis for implementation in
629 programming languages such as R or Python.

630

631 **Supplementary File 2: Annotated module repertoire framework**

632 This excel spreadsheet lists the 382 modules constituting this third generation of blood
633 transcriptome module repertoires. Included are number of genes, list of member genes by symbol
634 and probe ID, summarized functional annotations.


635 **Supplementary File 3: Module fingerprint grids of all 16 pathological and physiological**
636 **states**

637 This PDF documents contains the modular fingerprints generated for each of the 16 input
638 datasets.


639

SYSTEM:

**Blood
transcriptome**



**Multiple unweighted
co-clustering networks**



**One weighted
co-clustering
network**

STATES:






Disease 1

Disease 2

Disease 3






Scenario A

Co-expression
in three "states"








Scenario B

Co-expression
in two states



Scenario C


Co-expression
in one state



bioRxiv preprint doi: <https://doi.org/10.1101/525709>; this version posted January 23, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 1

Blood transcriptome repertoire - v1 (2008)



Blood transcriptome repertoire - v2 (2013)

N=56 publications





Figure 2

Input datasets

16 diseases /
physiological
states
985 Samples



K-means Clustering x 16

In how many datasets does Gene A clusters with Gene B?

✓ ✗ ✗ ✓ ✗ ✗ ✓ ✗ ✗ ✗ ✗ ✓ ✗ ✗ ✗ ✗


Co-Clustering Table

Genes	A	B	C	D	...
A		4	1	16	
B	4		0	0	
C	1	0		2	
D	16	0	2		
...					


Edges = co-clustering Events

Nodes = Genes

Weight



Weighted Co-Clustering Network



Selection of densely connected sub-networks = modules

382 Module repertoire (14,502 transcripts)





Figure 3

SLE patients (N=55) / Control subjects (N=14)



Module Annotation Grid






Figure 4


MS




S. aureus




COPD




Melanoma



SLE



TB



% Response





Figure 5



bioRxiv preprint doi: <https://doi.org/10.1101/525709>; this version posted January 23, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

% Response




Figure 6




Figure 7